blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP1455814

EP1455814 - PHARMACEUTICAL COMPOSITIONS COMPRISING UNACYLATED GHRELIN FOR USE IN THE TREATMENT OF INSULIN RESISTANCE [Right-click to bookmark this link]
Former [2004/38]PHARMACEUTICAL COMPOSITIONS COMPRISING UNACYLATED GHRELIN AND THERAPEUTICAL USES THEREOF
[2011/42]
StatusNo opposition filed within time limit
Status updated on  08.02.2013
Database last updated on 31.08.2024
Most recent event   Tooltip30.05.2014Lapse of the patent in a contracting state
New state(s): LU		published on 02.07.2014  [2014/27]
Applicant(s)For all designated states
Alizé Pharma SAS
15, Chemin du Saquin Espace Européen
69130 Ecully / FR
[2012/14]
Former [2009/32]For all designated states
Alizé Pharma SAS
15, Chemin du saquin Espace Européen
69130 Ecully / FR
Former [2007/50]For all designated states
Alizé Pharma SAS
13, Chemin de la Chonchance
69110 Ste-Foy-lès-Lyon / FR
Former [2007/49]For all designated states
Alizé Pharma Inc.
56 Kalvin Avenue
Montreal QC H2V 1T3 / CA
Former [2007/48]For all designated states
6551131 Canada Inc.
56 Kelvin Avenue
Montreal QC H2V 1T3 / CA
Former [2006/41]For all designated states
Erasmus MC
P.O. Box 2040
3000 CA Rotterdam / NL
Former [2004/38]For all designated states
THERATECHNOLOGIES INC.
2310 boulevard Alfred Nobel
Saint-Laurent, Québec H4S 2A4 / CA
Inventor(s)01 / GHIGO, Ezio
D'Azeglio 22
10125 Torino / IT
02 / VAN DER LELY, Aart Jan
Papavertuin 14
NL-2662 CW Bergschenhoek / NL
 [2004/38]
Representative(s)Regimbeau
139, rue Vendôme
69477 Lyon Cedex 06 / FR
[2012/49]
Former [2012/14]Tetaz, Franck Claude Edouard, et al
Cabinet Regimbeau 139, rue Vendôme
69477 Lyon Cedex 06 / FR
Former [2009/49]Tetaz, Franck Claude Edouard, et al
Cabinet Régimbeau 139, rue Vendôme
69477 Lyon Cedex 06 / FR
Former [2009/32]Tetaz, Franck Claude Edouard, et al
Cabinet Régimbeau 139, rue Vendôme
69477 Lyon Cedex 06 / FR
Former [2004/38]Hubert, Philippe, et al
Cabinet Beau de Loménie 158, rue de l'Université
75340 Paris Cédex 07 / FR
Application number, filing date02787266.218.12.2002
[2004/38]
WO2002CA01964
Priority number, dateCA2001236570418.12.2001         Original published format: CA 2365704
[2004/38]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO03051389
Date:26.06.2003
Language:EN
[2003/26]
Type: A2 Application without search report 
No.:EP1455814
Date:15.09.2004
Language:EN
The application published by WIPO in one of the EPO official languages on 26.06.2003 takes the place of the publication of the European patent application.
[2004/38]
Type: B1 Patent specification 
No.:EP1455814
Date:04.04.2012
Language:EN
[2012/14]
Search report(s)International search report - published on:EP12.09.2003
ClassificationIPC:A61P3/04, A61P3/10, A61K38/27
[2011/42]
CPC:
A61K38/27 (EP,US); A61P3/04 (EP); A61P3/10 (EP)
Former IPC [2004/38]A61K38/22, A61P3/04, A61P3/10
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   IE,   IT,   LI,   LU,   MC,   NL,   PT,   SE,   SI,   SK,   TR [2004/38]
TitleGerman:PHARMAZEUTISCHE ZUSAMMENSETZUNGEN ENTHALTEND NICHT-ACYLIERTES GHRELIN ZUR BEHANDLUNG VON INSULINRESISTENZ[2011/42]
English:PHARMACEUTICAL COMPOSITIONS COMPRISING UNACYLATED GHRELIN FOR USE IN THE TREATMENT OF INSULIN RESISTANCE[2011/42]
French:COMPOSITIONS PHARMACEUTIQUES COMPRENANT DE LA GHRELINE NON ACYLEE POUR LEUR UTILISATION DANS LE TRAITEMENT DE LA RESISTANCE A L'INSULINE[2011/42]
Former [2004/38]PHARMAZEUTISCHE ZUSAMMENSETZUNGEN ENTHALTEND NICHT-ACYLIERTES GHRELIN UND DEREN THERAPEUTISCHE VERWENDUNGEN
Former [2004/38]PHARMACEUTICAL COMPOSITIONS COMPRISING UNACYLATED GHRELIN AND THERAPEUTICAL USES THEREOF
Former [2004/38]COMPOSITIONS PHARMACEUTIQUES COMPRENANT DE LA GHRELINE NON ACYLEE ET UTILISATIONS THERAPEUTIQUES DE CES COMPOSITIONS
Entry into regional phase29.06.2004National basic fee paid 
29.06.2004Designation fee(s) paid 
29.06.2004Examination fee paid 
Examination procedure25.06.2003Request for preliminary examination filed
International Preliminary Examining Authority: EP
29.06.2004Examination requested  [2004/38]
30.06.2004Amendment by applicant (claims and/or description)
29.09.2006Despatch of a communication from the examining division (Time limit: M04)
06.02.2007Reply to a communication from the examining division
07.10.2008Despatch of a communication from the examining division (Time limit: M06)
16.04.2009Reply to a communication from the examining division
23.07.2010Despatch of a communication from the examining division (Time limit: M04)
16.11.2010Reply to a communication from the examining division
30.06.2011Despatch of a communication from the examining division (Time limit: M04)
24.08.2011Reply to a communication from the examining division
25.10.2011Communication of intention to grant the patent
20.02.2012Fee for grant paid
20.02.2012Fee for publishing/printing paid
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  29.09.2006
Opposition(s)07.01.2013No opposition filed within time limit [2013/11]
Fees paidRenewal fee
24.12.2004Renewal fee patent year 03
27.12.2005Renewal fee patent year 04
28.02.2007Renewal fee patent year 05
10.10.2007Renewal fee patent year 06
20.03.2008Renewal fee patent year 07
14.12.2009Renewal fee patent year 08
22.12.2010Renewal fee patent year 09
12.12.2011Renewal fee patent year 10
Penalty fee
Additional fee for renewal fee
31.12.200605   M06   Fee paid on   28.02.2007
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAT04.04.2012
BE04.04.2012
CY04.04.2012
CZ04.04.2012
DK04.04.2012
EE04.04.2012
FI04.04.2012
NL04.04.2012
SE04.04.2012
SI04.04.2012
SK04.04.2012
TR04.04.2012
BG04.07.2012
GR05.07.2012
PT06.08.2012
IE18.12.2012
LU18.12.2012
MC31.12.2012
[2014/27]
Former [2014/21]AT04.04.2012
BE04.04.2012
CY04.04.2012
CZ04.04.2012
DK04.04.2012
EE04.04.2012
FI04.04.2012
NL04.04.2012
SE04.04.2012
SI04.04.2012
SK04.04.2012
TR04.04.2012
BG04.07.2012
GR05.07.2012
PT06.08.2012
IE18.12.2012
MC31.12.2012
Former [2013/47]AT04.04.2012
BE04.04.2012
CY04.04.2012
CZ04.04.2012
DK04.04.2012
EE04.04.2012
FI04.04.2012
NL04.04.2012
SE04.04.2012
SI04.04.2012
SK04.04.2012
BG04.07.2012
GR05.07.2012
PT06.08.2012
IE18.12.2012
MC31.12.2012
Former [2013/34]AT04.04.2012
BE04.04.2012
CY04.04.2012
CZ04.04.2012
DK04.04.2012
EE04.04.2012
FI04.04.2012
NL04.04.2012
SE04.04.2012
SI04.04.2012
SK04.04.2012
BG04.07.2012
GR05.07.2012
PT06.08.2012
MC31.12.2012
Former [2013/33]AT04.04.2012
BE04.04.2012
CY04.04.2012
CZ04.04.2012
DK04.04.2012
EE04.04.2012
FI04.04.2012
NL04.04.2012
SE04.04.2012
SI04.04.2012
SK04.04.2012
GR05.07.2012
PT06.08.2012
MC31.12.2012
Former [2013/10]AT04.04.2012
BE04.04.2012
CY04.04.2012
CZ04.04.2012
DK04.04.2012
EE04.04.2012
FI04.04.2012
NL04.04.2012
SE04.04.2012
SI04.04.2012
SK04.04.2012
GR05.07.2012
PT06.08.2012
Former [2013/09]AT04.04.2012
BE04.04.2012
CY04.04.2012
DK04.04.2012
EE04.04.2012
FI04.04.2012
NL04.04.2012
SE04.04.2012
SI04.04.2012
GR05.07.2012
PT06.08.2012
Former [2013/08]AT04.04.2012
BE04.04.2012
CY04.04.2012
DK04.04.2012
FI04.04.2012
NL04.04.2012
SE04.04.2012
SI04.04.2012
GR05.07.2012
PT06.08.2012
Former [2013/07]AT04.04.2012
BE04.04.2012
CY04.04.2012
FI04.04.2012
SE04.04.2012
SI04.04.2012
GR05.07.2012
PT06.08.2012
Former [2013/04]BE04.04.2012
CY04.04.2012
FI04.04.2012
SE04.04.2012
SI04.04.2012
GR05.07.2012
PT06.08.2012
Former [2013/01]CY04.04.2012
FI04.04.2012
SE04.04.2012
SI04.04.2012
GR05.07.2012
PT06.08.2012
Former [2012/50]CY04.04.2012
FI04.04.2012
SE04.04.2012
SI04.04.2012
GR05.07.2012
Former [2012/49]CY04.04.2012
FI04.04.2012
SE04.04.2012
SI04.04.2012
Former [2012/48]FI04.04.2012
SE04.04.2012
Cited inInternational search[AD]WO0187335  (LILLY CO ELI [US], et al) [AD] 1-57 * claims *;
 [X]  - CASSONI PAOLA ET AL, "Identification, characterization, and biological activity of specific receptors for natural (ghrelin) and synthetic growth hormone secretagogues and analogs in human breast carcinomas and cell lines.", JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, (200104), vol. 86, no. 4, ISSN 0021-972X, pages 1738 - 1745, XP002243976 [X] 1,2,9,10,17-19,26,27,34,35,42,43,50,51 * page 1743, column L, paragraph 2 * * page 1744, column R, paragraph L *

DOI:   http://dx.doi.org/10.1210/jc.86.4.1738
 [A]  - TOSHINAI KOJI ET AL, "Upregulation of ghrelin expression in the stomach upon fasting, insulin-induced hypoglycemia, and leptin administration.", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, (20010316), vol. 281, no. 5, ISSN 0006-291X, pages 1220 - 1225, XP002243977 [A] 1-57 * page 1224, column L, paragraph 2; figure 2 *

DOI:   http://dx.doi.org/10.1006/bbrc.2001.4518
by applicantWO0156592
    - TOSHINAI ET AL., BIOCHEMICAL AND BIOPHYSICAL COMMUNICATIONS, (2001), vol. 281, pages 1220 - 1225
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.